Farxiga for Heart Failure - GoodRx
Nov 17, 2025 · Farxiga (dapagliflozin) is a Type 2 diabetes treatment that can also treat heart failure in people with or without diabetes. It belongs to a class of medications called sodium …
Why have you been prescribed FARXIGA? FARXIGA is a prescription drug used to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in …
Farxiga and Heart Failure: What You Need to Know - WebMD
Jun 27, 2024 · Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Here’s how it treats heart failure.
Understanding heart failure, and what you can do - FARXIGA
For adults with heart failure, when the heart cannot pump enough blood to the rest of the body, FARXIGA is a prescription medicine approved to reduce the risk of cardiovascular death, …
What Is Farxiga (Dapagliflozin)? - Heart-Failure.net
Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Farxiga (dapagliflozin) is used for adults with heart failure with reduced ejection fraction. It is specifically for those with Class II …
Farxiga for heart failure: How it works, effectiveness & more
Apr 19, 2024 · Farxiga is an oral prescription medicine containing the active ingredient dapagliflozin. It can be used to treat various conditions, including heart failure and Type 2 …
How Does Farxiga Work in Heart Failure?
Jun 4, 2025 · Farxiga, also known by its generic name dapagliflozin, is a medication initially developed to treat type 2 diabetes. However, it is now a breakthrough treatment for heart …
Medications Used to Treat Heart Failure
Jun 17, 2025 · Heart failure medication can reduce symptoms and improve energy levels. People with heart failure need more than one medication to treat symptoms. Work with your health …
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The wholesale acquisition cost of 30-day supply of Farxiga is $565.30. 6 CONCLUSION ― Addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) to …
Farxiga extended in the US to reduce risk of cardiovascular death …
May 9, 2023 · AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure …